Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.
General Instructions provides useful general background information for successfully completing forms.
2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.
Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.
Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.
Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.
Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms
Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.
Appendices provide additional information beyond the scope of the other manuals.
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
|11/29/2021||Appendix D: How to Distinguish Infusion Types||Modify||Updated to include gene therapy information|
|10/27/2021||4100: Cellular Therapy Essential Data Follow-Up||Modify||Added the commercially available product names ‘Breyanzi’ and ‘Abecma’ to the red warning box below question 148: This question will enable only if the commercially available product ‘Kymriah’, ‘Breyanzi’, or ‘Abecma’ is selected in question 1 and can only be completed on the 100 day and 6 month follow-up forms.|
|9/15/2021||Cellular Therapy Manuals||Add||Added statement for REMS reporting: REMS reporting: infusions can be reported without research consent if the center is utilizing CIBMTR to support their REMS reporting needs in meeting the requirements for the commercially available CAR-T products.|
|5/12/2021||4100: Cellular Therapy Essential Data Follow-Up||Add||Added new example 4 for hypogammaglobulinemia resolution date when testing is not exactly at 3 months.|
|3/17/2021||4000: Cellular Therapy Essential Data Pre-Infusion||Modify|| Clarification added to the blue note box about reporting co-morbidities within 6 months of the cellular therapy: Please report co-morbidities that
|1/7/2021||4100: Cellular Therapy Essential Data Follow-Up||Add||Clarified when to report hypogammaglobulinemia, how to report date of onset and date of resolution. Several examples have been added.|
Need more help with this?
Don’t hesitate to contact us here.